AstraZeneca Annual Report and Financial Statements 70 Form 20-F Information 2003 Notes to the Financial Statements continued 3 Exceptional items 2003 2002 2001 $m $m $m Accrual related to Zoladex investigation 350 Integration and synergy costs 202 Exceptional items included in operating profit 350 202 Profit on sale of fixed assets 10 Total exceptional items before taxation 350 192 Net taxation credit 54 Total exceptional items after taxation 350 138 There were no exceptional items in 2003.
As set out in more detail in Note 31, the Company announced on 20 June 2003 a settlement of the US Department of Justice investigation into the US sales and marketing practices for Zoladex goserelin acetate implant.
Negotiations towards this settlement were sufficiently advanced to recognise an exceptional charge of $350m at 31 December 2002.
The difference between the final settlement of $355m and the 2002 exceptional charge of $350m amounting to $5m has been charged to operating profit before exceptional items in 2003.
The integration and synergy programme initiated in 1999 was completed during 2001, with final exceptional charges of $202m, principally for manpower related costs, IT costs and contractors.
4 Net interest 2003 2002 2001 $m $m $m Interest receivable and similar income from investments Securities 21 21 19 Short term deposits 75 90 179 Exchange gains 19 61 115 117 199 Interest payable and similar charges Loan interest 7 10 32 Interest on short term borrowings and other financing costs 16 51 35 Discount on liability 3 10 15 Exchange losses 16 12 26 87 94 Net interest receivable 89 30 105
